electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
electroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
electroCore (Nasdaq: ECOR) announced publication in JAMA Network Open of a cluster randomized clinical trial evaluating a modified Quell device added to outpatient physical therapy for fibromyalgia.
Among 384 participants, PT-Quell showed greater pain and fatigue improvements, with benefits seen by 30 days and lasting up to six months.
Loading...
Loading translation...
Positive
Cluster randomized trial of 384 fibromyalgia participants completed baseline data collection
PT-Quell group showed 1.2-point greater reduction in movement-evoked pain at day 60
Statistically significant improvements in multiple secondary measures versus PT-only
Quell benefits observed within 30 days and sustained up to six months
81% of respondents found Quell helpful; 55% continued daily use
Quell described as first and only non-drug, FDA-cleared device indicated for fibromyalgia
Negative
None.
News Market Reaction – ECOR
-5.60%
1 alert
-5.60%Session close to close
$51.35MMarket Cap
0.0xRel. Volume
In the May 13 session, ECOR declined 5.60%, reflecting a notable negative market reaction.
The stock moved -5.6% in the session following this news. A negative reaction despite positive JAMA ...
Analysis
The stock moved -5.6% in the session following this news. A negative reaction despite positive JAMA fibromyalgia data would fit a pattern seen around the May 6, 2026 earnings release, where strong growth coincided with a -5.86% move. The trial’s 384-patient result and P<.001> pain reduction may be overshadowed by concerns from recent SEC filings about net losses, stockholders’ deficit, and going-concern language, as well as existing resale registration overhang.
Key Figures
Trial enrollment:384 participantsPT-Quell group size:191 individualsPT-only group size:193 individuals+5 more
Market Movers Investor Summit presentation and one-on-one investor meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news and conference updates have often coincided with positive or stable price reactions, while a strong earnings update saw a negative move, indicating occasional sell-the-news dynamics on fundamentally positive releases.
Recent Company History
Over the last few weeks, ECOR issued several updates, including investor conference presentations on April 28 and May 8, 2026, and product recognition for TAC-STIM on April 30, 2026. These items generally aligned with modest positive price moves. By contrast, the May 6, 2026 Q1 earnings release, which highlighted strong growth and margin performance, was followed by a -5.86% reaction. Today’s JAMA-reported Quell fibromyalgia data extends the company’s narrative around nonpharmacological neuromodulation therapies.
"“Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia..."
Transcutaneous electrical nerve stimulation (TENS) is a noninvasive pain-relief method that uses a small battery-powered device to send gentle electrical pulses through adhesive pads placed on the skin, like a light, rhythmic massage delivered by electricity. For investors, TENS matters because commercial success depends on clinical evidence, regulatory clearance, insurance coverage and consumer acceptance—factors that influence sales, reimbursement and growth potential in the medical device and healthcare markets.
fibromyalgiamedical
"People With Fibromyalgia: A Cluster Randomized Clinical Trial.” The study evaluated..."
Fibromyalgia is a long-term condition that causes widespread body pain, extreme tiredness, and problems with sleep, memory and mood; people often feel unusually sensitive to normal touch or pressure, and symptoms can fluctuate from day to day. It matters to investors because it affects workforce productivity, healthcare spending, and demand for treatments—so advances in diagnostics, drugs, or care delivery can change market size and company prospects, much like a fuel problem that reduces a car’s performance and reliability.
movement-evoked painmedical
"At day 60, reduction in movement-evoked pain was significantly greater..."
Movement-evoked pain is pain that is reliably triggered or worsened when a person moves a body part, like joint pain flaring only when standing or lifting. For investors, it matters because it is often used as a measurable endpoint in clinical trials and product claims for pain treatments or devices—like a car test showing performance under load—so changes in this measure can directly affect regulatory approval, market size, pricing and reimbursement prospects.
95% CItechnical
"between-group difference, −1.2 points [95% CI, −1.6 to −0.7]; P<.001"
A 95% confidence interval is a range around a measured value that conveys how much uncertainty there is: if the same measurement or analysis were repeated many times, about 95% of those ranges would contain the true value. Think of it like the spread of where arrows land around a bullseye—narrower spread means more precision. Investors use it to judge how reliable an estimate or forecast is and to compare the risk of different outcomes.
P<.001technical
"difference, −1.2 points [95% CI, −1.6 to −0.7]; P<.001"
A notation from statistics meaning the observed result has less than a 0.1% probability of arising by random chance alone. Investors see p<.001 as strong evidence that a reported effect — such as a drug benefit, safety signal, or market test result — is unlikely to be a fluke, so the underlying claim is more trustworthy. Think of it as finding a rare coin in a handful of flips: it makes you much more confident the coin is special rather than lucky.
nonpharmacologicalmedical
"an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient..."
Nonpharmacological describes treatments or interventions that do not use drugs, such as lifestyle changes, physical therapy, medical devices, counseling, or surgical procedures. For investors, these options matter because they follow different regulatory paths, cost structures and reimbursement rules than medicines, which can affect development time, market size and the types of partners or buyers attracted—think of choosing a tool or technique instead of a chemical solution.
FIQRmedical
"resting fatigue, and fibromyalgia impact (FIQR) during the randomized phase."
FIQR stands for the Fibromyalgia Impact Questionnaire Revised, a patient-completed survey that measures how fibromyalgia affects daily life, including pain, fatigue, sleep, mood and ability to function. Investors care because FIQR scores are often used as primary or secondary endpoints in clinical trials to show whether a treatment meaningfully improves patients’ lives; strong, consistent improvements can support regulatory approval and boost a drug’s commercial prospects, much like a reliable customer satisfaction score predicts product success.
ROCKAWAY, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today the publication of new clinical findings in JAMA Network Open titled, “Transcutaneous Electrical Nerve Stimulation and Pain With Movement in People With Fibromyalgia: A Cluster Randomized Clinical Trial.”
The study evaluated the use of a modified Quell device, an FDA-authorized nonpharmacological wearable stimulation device, when added to outpatient physical therapy (“PT”) for people with fibromyalgia. The trial enrolled 384 participants [that completed baseline data collection], including 191 individuals in the PT-Quell group and 193 individuals in the PT-only group.
At day 60, reduction in movement-evoked pain was significantly greater in the PT-Quell group compared with the PT-only group, (between-group difference, −1.2 points [95% CI, −1.6 to −0.7]; P<.001), and statistically significant improvements favoring the PT-Quell group were also observed across several other secondary measures, including resting pain, pain interference, movement-evoked fatigue, resting fatigue, and fibromyalgia impact (FIQR) during the randomized phase. The benefits of Quell were observed within 30 days and were sustained for up to six months. Among respondents, 81% reported finding Quell helpful, and 55% continued to use Quell daily.
“Fibromyalgia represents a significant market opportunity, with conservative estimates suggesting that approximately 2% to 4% of the population is affected by the condition,” stated Peter Staats, MD, Chief Medical Officer at electroCore. “Quell is the first and only non-drug, FDA-cleared device indicated for fibromyalgia and the study results suggest that it may be a safe, inexpensive, and readily available treatment option for people living with the inflammatory condition.”
About electroCore, Inc. electroCore, Inc. is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products, gammaCore® non-invasive vagus nerve stimulation (nVNS) and Quell® neurostimulator, treat chronic pain syndromes through non-invasive neuromodulation technology. Additionally, the company commercializes its handheld, and personal use Truvaga™ and TAC-STIM™ nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
Forward-Looking Statements This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about anticipated results from the study using physical therapy in conjunction with Quell Fibromyalgia in patients in an outpatient setting in patients with fibromyalgia, the use of Quell Fibromyalgia in conjunction with physical therapy to minimize pain and fatigue, the Company’s future business strategies, growth opportunities, prospects, product development, and market expansion, and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” “may,” “potential,” and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the performance of Quell Fibromyalgia as a technology to reduce pain and fatigue, the ability of the Company to develop and commercialize new products or technologies, its ability to obtain regulatory clearance or approval for new indications, electroCore’s results of operations and financial performance, inflation and currency fluctuations, and any expectations electroCore may have with respect thereto, as well as competition in the industry in which electroCore operates and overall economic and market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.
What did electroCore (ECOR) announce about Quell and fibromyalgia on May 13, 2026?
electroCore announced JAMA Network Open publication of a clinical trial of its Quell device for fibromyalgia. According to electroCore, adding Quell to outpatient physical therapy improved movement-evoked pain and several secondary outcomes versus physical therapy alone over up to six months.
What were the key results of the Quell fibromyalgia clinical trial supporting electroCore (ECOR)?
The trial found greater reduction in movement-evoked pain when Quell was added to physical therapy. According to electroCore, the between-group difference at day 60 was −1.2 points, with significant improvements also seen in resting pain, pain interference, fatigue, and fibromyalgia impact scores.
How many patients were enrolled in the Quell plus physical therapy fibromyalgia study for electroCore (ECOR)?
The study enrolled 384 participants with fibromyalgia who completed baseline data collection. According to electroCore, 191 participants were assigned to the PT-Quell group and 193 to the PT-only group in this cluster randomized clinical trial published in JAMA Network Open.
How quickly did Quell show benefits for fibromyalgia patients in the electroCore (ECOR) study?
Benefits from Quell were observed within 30 days of starting therapy. According to electroCore, these improvements, including reduced movement-evoked pain and better fatigue and fibromyalgia impact measures, were sustained for up to six months during the randomized phase of the trial.
What percentage of fibromyalgia patients continued daily Quell use in the electroCore (ECOR) trial?
Among respondents in the study, 55% continued to use Quell daily after the trial period. According to electroCore, 81% of respondents reported finding the Quell device helpful when used alongside outpatient physical therapy for fibromyalgia management.
Is Quell FDA-cleared for fibromyalgia and how is it positioned by electroCore (ECOR)?
Quell is described as the first and only non-drug, FDA-cleared device indicated for fibromyalgia. According to electroCore, it is a wearable, nonpharmacological nerve stimulation option that may offer a safe, inexpensive, and readily available treatment alongside outpatient physical therapy.
How large is the potential fibromyalgia market for electroCore (ECOR) and Quell?
electroCore highlights fibromyalgia as a significant market opportunity for Quell. According to electroCore, conservative estimates suggest approximately 2% to 4% of the population is affected by fibromyalgia, supporting commercial potential for an FDA-cleared, non-drug wearable stimulation device.
